Researchers studied the relationship between 3 dermatological immune-mediated inflammatory diseases and COVID-19.

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient response without serious adverse effects.

Topical Steroid Withdrawal Diagnostic Criteria Defined by NIH Researchers - Criteria May Help Guide Treatment of Dermatitis ...

Ocular surface disease symptoms in individuals with comorbid atopic dermatitis are more common and severe, and self-rated vision is worse.

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...